Institution · Serpin Pharma (United States)

Most cited papers from Serpin Pharma (United States)

Serpin Pharma (United States)

What are the most cited papers from Serpin Pharma (United States)?

The most cited paper from Serpin Pharma (United States) is "The Role of IKKβ in Venezuelan Equine Encephalitis Virus Infection" (Moushimi Amaya, Kelsey Voss, Gavin C. Sampey et al., 2014), with 47 citations. Next come "Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction" (45) and "Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription" (27).

Published FieldAccess

Showing 10 of 10 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The Role of IKKβ in Venezuelan Equine Encephalitis Virus Infection Moushimi Amaya, Kelsey Voss, Gavin C. Sampey et al. · PLoS ONE Open access	19 Feb 2014	47
2	Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction Stefano A Toldo, Dana Austin, Adolfo Gabriele Mauro et al. · JACC Basic to Translational Science Open access	Oct 2017	45
3	Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription Catherine DeMarino, Maria Cowen, Pooja Khatkar et al. · Cells Open access	18 Feb 2022	27
4	α1‐Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain Zixuan Wang, Stefano Martellucci, Alicia Van Enoo et al. · The FASEB Journal Open access	9 Dec 2021	16
5	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers George F. Wohlford, Leo Francis Buckley, Dinesh Kadariya et al. · PLoS ONE Open access	6 May 2021	16
6	SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System Yemmy Soler, Myosotys Rodriguez, Dana Austin et al. · Cells Open access	15 Feb 2023	11
7	Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction Benjamin W. Van Tassell, George F. Wohlford, Marco Giuseppe Del Buono et al. · Journal of Cardiovascular Pharmacology	12 Jul 2022	7
8	Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC Madison Isbell, Faridoddin Mirshahi, Hussein F. Aqbi et al. · Cancers Open access	9 Nov 2022	5
9	Additional file 1 of Efficacy and safety of SP16 in preventing acute kidney injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart–lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial Tilman Jobst‐Schwan, Karl Bihlmaier, Dana Austin et al. · Figshare Open access	28 Aug 2026	0
10	Efficacy and safety of SP16 in preventing acute kidney injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart–lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial Tilman Jobst‐Schwan, Karl Bihlmaier, Dana Austin et al. · Trials Open access	28 Aug 2026	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.